Document Detail

Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid.
MedLine Citation:
PMID:  21372118     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: There is increasing evidence of B-cell involvement in the pathogenesis of multiple sclerosis (MS). B-cell activating factor (BAFF) has an essential role in B-cell homeostasis. The chemokine CXCL13 has an important role in the formation and maintenance of B-cell follicles.
OBJECTIVE: To measure BAFF and CXCL13 levels in the cerebrospinal fluid (CSF) of patients with MS compared to patients with other neurological diseases.
METHODS: Cytokine/chemokine levels were measured by an enzyme-linked immunosorbent assay (ELISA).
RESULTS: In MS patients, BAFF levels were highest in patients with secondary progressive disease, and were higher during relapse in patients with relapsing-remitting and secondary progressive disease. CXCL13 levels were also higher during relapse. There was a positive correlation between CXCL13 and the IgG index, and an inverse correlation between BAFF and the IgG index. The implications of this finding are discussed.
CONCLUSION: During relapse, we found various positive correlations between BAFF, CXCL13 and the cytokines IL-6 and IL-10. These findings show that molecules that are essential for B-cell recruitment, survival, maturation and function may be working in concert to affect B-cell homeostasis in MS and contribute to the pathophysiology of the disease.
Samia Ragheb; Yanfeng Li; Kirk Simon; Stephen VanHaerents; Daniela Galimberti; Milena De Riz; Chiara Fenoglio; Elio Scarpini; Robert Lisak
Related Documents :
17019408 - Fluvoxamine treatment and d2 receptors: a pet study on ocd drug-naïve patients.
887698 - Working with a borderline patient.
10207288 - Ethics in psychiatric diagnosis from a psychodynamic perspective.
16377368 - Substance abuse and recovery in a psychiatric intensive care unit.
8147448 - Multisite data reanalysis of the validity of rapid cycling as a course modifier for bip...
6823808 - Prazosin therapy for refractory variant angina.
Publication Detail:
Type:  Journal Article     Date:  2011-03-03
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  17     ISSN:  1477-0970     ISO Abbreviation:  Mult. Scler.     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-21     Completed Date:  2011-10-14     Revised Date:  2014-03-14    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  England    
Other Details:
Languages:  eng     Pagination:  819-29     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
B-Cell Activating Factor / cerebrospinal fluid*
B-Lymphocytes / immunology
Biological Markers / cerebrospinal fluid
Chemokine CXCL13 / cerebrospinal fluid*
Enzyme-Linked Immunosorbent Assay
Immunoglobulin G / cerebrospinal fluid
Interleukin-10 / cerebrospinal fluid
Interleukin-6 / cerebrospinal fluid
Middle Aged
Multiple Sclerosis, Chronic Progressive / cerebrospinal fluid*,  immunology
Multiple Sclerosis, Relapsing-Remitting / cerebrospinal fluid*,  immunology
Oligoclonal Bands / cerebrospinal fluid
Reg. No./Substance:
0/B-Cell Activating Factor; 0/Biological Markers; 0/CXCL13 protein, human; 0/Chemokine CXCL13; 0/IL10 protein, human; 0/IL6 protein, human; 0/Immunoglobulin G; 0/Interleukin-6; 0/Oligoclonal Bands; 0/TNFSF13B protein, human; 130068-27-8/Interleukin-10
Erratum In:
Mult Scler. 2012 Jan;doi/10.1177/1352458511436287

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Critical appraisal of animal models of multiple sclerosis.
Next Document:  Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis.